Potassium-competitive acid blockers and gastroesophageal reflux disease

作     者：Wattana Leowattana Tawithep Leowattana 

作者机构：Clinical Tropical MedicineFaculty of Tropical MedicineMahidol UniversityBangkok 10400Thailand Department of MedicineFaculty of MedicineSrinakharinwirot UniversityBangkok 10110Thailand 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2022年第28卷第28期

页      面：3608-3619页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Potassium-competitive acid blocker Gastroesophageal reflux disease Proton pump inhibitors Treatment outcome Proton pump inhibitor-refractory patients Esophageal mucosal resistance 

摘      要：Proton pump inhibitors(PPIs),the most commonly used antisecretory medications in the management of reflux illness,virtually eliminate elective surgery for ulcer disease,and relegate anti-reflux surgery to patients with gastroesophageal reflux disease(GERD)who are inadequately managed by medical ***,PPI medications still leave some therapeutic demands of GERD ***,up to 40%-55%of daily PPI users have chronic symptoms,due to PPI ***-competitive acid blockers(P-CABs)transcend many of the problems and limits of PPIs,delivering quick,powerful,and extended acid suppression and allowing for treatment of numerous unmet ***,it has become clear that compromised mucosal integrity plays a role in the etiology of *** a result,esophageal mucosal protection has emerged as a novel and potential treatment *** increasing body of research demonstrates that when P-CABs are used as primary drugs or add-on drugs(to regular treatment),they provide a considerable extra benefit,particularly in alleviating symptoms that do not respond to PPI therapy.